Ignite Creation Date:
2024-05-06 @ 1:18 PM
Last Modification Date:
2024-10-26 @ 1:12 PM
Study NCT ID:
NCT03983954
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-02-22
First Post:
2019-05-27
Brief Title:
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors
Sponsor:
NeoTX Therapeutics Ltd
Organization:
NeoTX Therapeutics Ltd
Organization Data
Organization:
NeoTX Therapeutics Ltd
Class:
INDUSTRY
Study ID:
127-CL-01
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
NeoTX Therapeutics Ltd
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| AstraZeneca | INDUSTRY |